Here are three quick notes:
1. The poster presentations highlight data from the oliceridine program, which compares oliceridine to conventional opioid analgesics.
2. Oliceridine was designed to deliver an improved analgesic profile. It has been granted ‘Breakthrough Therapy’ designation by the FDA.
3. The presentations will include key data from the company’s phase 2b trial focusing on acute pain following abdominoplasty.
More articles on anesthesia:
8 anesthesiology groups named in Colorado Medicaid over-billing probe: 4 key notes
NAPA acquires Anesthesia Care Group: 3 things to know
Dr. John Brock-Utne releases book on clinical research quandaries: 3 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
